Literature DB >> 33858327

Defining the temporal evolution of gut dysbiosis and inflammatory responses leading to hepatocellular carcinoma in Mdr2 -/- mouse model.

J Behary1,2,3, A E Raposo1,2, N M L Amorim1,2, H Zheng1,2, L Gong1,2, E McGovern1,2, J Chen4, K Liu4,5, J Beretov1,6, C Theocharous6, M T Jackson1,2, J Seet-Lee1,2, G W McCaughan4,5, E M El-Omar1,2,3, A Zekry7,8,9.   

Abstract

BACKGROUND: Emerging evidence implicates the gut microbiome in liver inflammation and hepatocellular carcinoma (HCC) development. We aimed to characterize the temporal evolution of gut dysbiosis, in relation to the phenotype of systemic and hepatic inflammatory responses leading to HCC development. In the present study, Mdr2 -/- mice were used as a model of inflammation-based HCC. Gut microbiome composition and function, in addition to serum LPS, serum cytokines/chemokines and intrahepatic inflammatory genes were measured throughout the course of liver injury until HCC development.
RESULTS: Early stages of liver injury, inflammation and cirrhosis, were characterized by dysbiosis. Microbiome functional pathways pertaining to gut barrier dysfunction were enriched during the initial phase of liver inflammation and cirrhosis, whilst those supporting lipopolysaccharide (LPS) biosynthesis increased as cirrhosis and HCC ensued. In parallel, serum LPS progressively increased during the course of liver injury, corresponding to a shift towards a systemic Th1/Th17 proinflammatory phenotype. Alongside, the intrahepatic inflammatory gene profile transitioned from a proinflammatory phenotype in the initial phases of liver injury to an immunosuppressed one in HCC. In established HCC, a switch in microbiome function from carbohydrate to amino acid metabolism occurred.
CONCLUSION: In Mdr2 -/- mice, dysbiosis precedes HCC development, with temporal evolution of microbiome function to support gut barrier dysfunction, LPS biosynthesis, and redirection of energy source utilization. A corresponding shift in systemic and intrahepatic inflammatory responses occurred supporting HCC development. These findings support the notion that gut based therapeutic interventions could be beneficial early in the course of liver disease to halt HCC development.

Entities:  

Keywords:  Cirrhosis; Dysbiosis; Hepatocarcinogenesis; Hepatocellular carcinoma; Inflammatory response; Intrahepatic inflammation; Lipopolysaccharide; Mdr2; Microbiome; Microbiota

Year:  2021        PMID: 33858327     DOI: 10.1186/s12866-021-02171-9

Source DB:  PubMed          Journal:  BMC Microbiol        ISSN: 1471-2180            Impact factor:   3.605


  29 in total

1.  Obesity-induced gut microbial metabolite promotes liver cancer through senescence secretome.

Authors:  Shin Yoshimoto; Tze Mun Loo; Koji Atarashi; Hiroaki Kanda; Seidai Sato; Seiichi Oyadomari; Yoichiro Iwakura; Kenshiro Oshima; Hidetoshi Morita; Masahira Hattori; Masahisa Hattori; Kenya Honda; Yuichi Ishikawa; Eiji Hara; Naoko Ohtani
Journal:  Nature       Date:  2013-06-26       Impact factor: 49.962

2.  Induction of cross-tolerance by lipopolysaccharide and highly purified lipoteichoic acid via different Toll-like receptors independent of paracrine mediators.

Authors:  M D Lehner; S Morath; K S Michelsen; R R Schumann; T Hartung
Journal:  J Immunol       Date:  2001-04-15       Impact factor: 5.422

3.  Hepatocellular Carcinoma Is Associated With Gut Microbiota Profile and Inflammation in Nonalcoholic Fatty Liver Disease.

Authors:  Francesca Romana Ponziani; Sherrie Bhoori; Chiara Castelli; Lorenza Putignani; Licia Rivoltini; Federica Del Chierico; Maurizio Sanguinetti; Daniele Morelli; Francesco Paroni Sterbini; Valentina Petito; Sofia Reddel; Riccardo Calvani; Chiara Camisaschi; Anna Picca; Alessandra Tuccitto; Antonio Gasbarrini; Maurizio Pompili; Vincenzo Mazzaferro
Journal:  Hepatology       Date:  2018-07-10       Impact factor: 17.425

4.  Gut Microbiota Promotes Obesity-Associated Liver Cancer through PGE2-Mediated Suppression of Antitumor Immunity.

Authors:  Tze Mun Loo; Fumitaka Kamachi; Yoshihiro Watanabe; Shin Yoshimoto; Hiroaki Kanda; Yuriko Arai; Yaeko Nakajima-Takagi; Atsushi Iwama; Tomoaki Koga; Yukihiko Sugimoto; Takayuki Ozawa; Masaru Nakamura; Miho Kumagai; Koichi Watashi; Makoto M Taketo; Tomohiro Aoki; Shuh Narumiya; Masanobu Oshima; Makoto Arita; Eiji Hara; Naoko Ohtani
Journal:  Cancer Discov       Date:  2017-02-15       Impact factor: 39.397

5.  A new Mdr2(-/-) mouse model of sclerosing cholangitis with rapid fibrosis progression, early-onset portal hypertension, and liver cancer.

Authors:  Naoki Ikenaga; Susan B Liu; Deanna Y Sverdlov; Shuhei Yoshida; Imad Nasser; Qingen Ke; Peter M Kang; Yury Popov
Journal:  Am J Pathol       Date:  2014-12-02       Impact factor: 4.307

Review 6.  Regulation of type I interferon responses.

Authors:  Lionel B Ivashkiv; Laura T Donlin
Journal:  Nat Rev Immunol       Date:  2014-01       Impact factor: 53.106

7.  Molecular mechanisms of liver carcinogenesis in the mdr2-knockout mice.

Authors:  Mark Katzenellenbogen; Lina Mizrahi; Orit Pappo; Naama Klopstock; Devorah Olam; Jasmine Jacob-Hirsch; Ninette Amariglio; Gideon Rechavi; Eytan Domany; Eithan Galun; Daniel Goldenberg
Journal:  Mol Cancer Res       Date:  2007-11       Impact factor: 5.852

8.  Recognition of lipopeptides by Toll-like receptors.

Authors:  Kiyoshi Takeda; Osamu Takeuchi; Shizuo Akira
Journal:  J Endotoxin Res       Date:  2002

9.  Dysregulated Microbial Fermentation of Soluble Fiber Induces Cholestatic Liver Cancer.

Authors:  Vishal Singh; Beng San Yeoh; Benoit Chassaing; Xia Xiao; Piu Saha; Rodrigo Aguilera Olvera; John D Lapek; Limin Zhang; Wei-Bei Wang; Sijie Hao; Michael D Flythe; David J Gonzalez; Patrice D Cani; Jose R Conejo-Garcia; Na Xiong; Mary J Kennett; Bina Joe; Andrew D Patterson; Andrew T Gewirtz; Matam Vijay-Kumar
Journal:  Cell       Date:  2018-10-18       Impact factor: 41.582

Review 10.  The gut microbiome and liver cancer: mechanisms and clinical translation.

Authors:  Le-Xing Yu; Robert F Schwabe
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2017-07-05       Impact factor: 46.802

View more
  2 in total

Review 1.  Modulation of the Gut Microbiome to Improve Clinical Outcomes in Hepatocellular Carcinoma.

Authors:  Sj Shen; Saroj Khatiwada; Jason Behary; Rachel Kim; Amany Zekry
Journal:  Cancers (Basel)       Date:  2022-04-23       Impact factor: 6.575

Review 2.  The gut-liver axis: host microbiota interactions shape hepatocarcinogenesis.

Authors:  Maruhen A D Silveira; Steve Bilodeau; Tim F Greten; Xin Wei Wang; Giorgio Trinchieri
Journal:  Trends Cancer       Date:  2022-03-21
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.